Tedros Adhanom Ghebreyesus & Merck Group

Tedros Adhanom Ghebreyesus: As WHO Director-General, he declared the outbreak a global emergency, raising international awareness and mobilizing resources.

Merck Group: Merck Group's Ervebo vaccine is being deployed in the outbreak response, potentially increasing sales. However, its efficacy against the Bundibugyo strain is unproven, and the trial outcome will be critical.

Tedros Adhanom Ghebreyesus: WHO Director-General, making multiple visits to DRC, urging scale-up and warning the outbreak is outpacing response. His leadership is central to global health response.

Merck Group: Manufacturer of RVSV-ZEBOV vaccine, which is being considered for cross-protection trials. Its vaccine could play a role in the response, benefiting its reputation.

Tedros Adhanom Ghebreyesus: As WHO chief, he voiced concern and reaffirmed vaccine safety, adding international pressure on the administration.

Merck Group: As a major MMR manufacturer, it faces potential regulatory and market changes. It stated no scientific evidence supports splitting the vaccine, and it may face pressure to develop separate shots.

Tedros Adhanom Ghebreyesus: WHO Director-General warned that progress is fragile without sustained funding.

Merck Group: Announced plans to allow generic production of alimatravir, potentially expanding market access.